Literature DB >> 20731580

Hospitalist to home: outpatient parenteral antimicrobial therapy at an academic center.

Hien H Nguyen1.   

Abstract

The cost of health care in the United States continues to increase as an aging population places increasing demands on institutions providing health care. Moreover, despite increases in the complexity and cost of health care, reimbursement for some services has been reduced or denied. Thus, the current challenge at many hospitals throughout the United States is to deliver high-quality health care while maximizing resource use and reducing costs without compromising clinical outcomes. We describe an answer to the challenge that combines 2 emerging treatment models in an academic setting: hospital-based physicians and outpatient parenteral antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20731580     DOI: 10.1086/653523

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity.

Authors:  C Gardiol; R Voumard; C Cochet; S de Vallière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-17       Impact factor: 3.267

2.  Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection.

Authors:  David A Talan; Bisan A Salhi; Gregory J Moran; William R Mower; Yu-Hsiang Hsieh; Anusha Krishnadasan; Richard E Rothman
Journal:  West J Emerg Med       Date:  2014-12-10

3.  A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis.

Authors:  Pallavi Bedi; Manjit K Sidhu; Lucienne S Donaldson; James D Chalmers; Maeve P Smith; Kim Turnbull; Joanna L Pentland; Jenny Scott; Adam T Hill
Journal:  NPJ Prim Care Respir Med       Date:  2014-10-23       Impact factor: 2.871

4.  Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.

Authors:  Ivar S Jensen; Thomas P Lodise; Weihong Fan; Chining Wu; Philip L Cyr; David P Nicolau; Scott DuFour; Katherine A Sulham
Journal:  Clin Drug Investig       Date:  2016-02       Impact factor: 2.859

5.  Value and Clinical Impact of an Infectious Disease-Supervised Outpatient Parenteral Antibiotic Therapy Program.

Authors:  Russell M Petrak; Nathan C Skorodin; Robert M Fliegelman; David W Hines; Vishnu V Chundi; Brian P Harting
Journal:  Open Forum Infect Dis       Date:  2016-10-19       Impact factor: 3.835

6.  Perspectives of United States-based Infectious Diseases Physicians on Outpatient Parenteral Antimicrobial Therapy Practice.

Authors:  Yasir Hamad; Michael A Lane; Susan E Beekmann; Philip M Polgreen; Sara C Keller
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

7.  Cost-analysis of inpatient and outpatient parenteral antimicrobial therapy in orthopaedics: A systematic literature review.

Authors:  Christoph Kolja Boese; Philipp Lechler; Michael Frink; Michael Hackl; Peer Eysel; Christian Ries
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

Review 8.  Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.

Authors:  Ann L N Chapman; Sanjay Patel; Carolyne Horner; Helen Green; Achyut Guleri; Sara Hedderwick; Susan Snape; Julie Statham; Elizabeth Wilson; Mark Gilchrist; R Andrew Seaton
Journal:  JAC Antimicrob Resist       Date:  2019-08-26

Review 9.  Managing an outpatient parenteral antibiotic therapy team: challenges and solutions.

Authors:  Jenana Halilovic; Cinda L Christensen; Hien H Nguyen
Journal:  Ther Clin Risk Manag       Date:  2014-06-18       Impact factor: 2.423

10.  Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections.

Authors:  David A Talan; William R Mower; Frank A Lovecchio; Richard E Rothman; Mark T Steele; Katelyn Keyloun; Patrick Gillard; Ronald Copp; Gregory J Moran
Journal:  Acad Emerg Med       Date:  2021-05-05       Impact factor: 3.451

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.